Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etentamig + Iberdomide in R/R Multiple Myeloma
NCT06896916Phase 1Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Aug 2025
- Primary completion
- Mar 2036
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 1, open-label trial of etentamig in multiple myeloma (MM) (3 arms), sponsored by AbbVie Inc. Primary endpoints: Dose-Limiting Toxicities at 56 days and Adverse Events at 129 months. Started Aug 2025; status: recruiting.
02
Drugs
etentamig
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06896916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06896916.